Skip to main content
Erschienen in: Clinical Rheumatology 1/2017

26.05.2016 | Case Based Review

Describing Kawasaki shock syndrome: results from a retrospective study and literature review

verfasst von: Andrea Taddio, Eleonora Dei Rossi, Lorenzo Monasta, Serena Pastore, Alberto Tommasini, Loredana Lepore, Gabriele Bronzetti, Edoardo Marrani, Biancamaria D’Agata Mottolese, Gabriele Simonini, Rolando Cimaz, Alessandro Ventura

Erschienen in: Clinical Rheumatology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Kawasaki shock syndrome (KSS) is a rare manifestation of Kawasaki disease (KD) characterized by systolic hypotension or clinical signs of poor perfusion. The objectives of the study are to describe the main clinical presentation, echocardiographic, and laboratory findings, as well as the treatment options and clinical outcomes of KSS patients when compared with KD patients. This is a retrospective study. All children referred to two pediatric rheumatology units from January 1, 2012, to December 31, 2014, were enrolled. Patients were divided into patients with or without KSS. We compared the two groups according to the following variables: sex, age, type of KD (classic, with less frequent manifestations, or incomplete), clinical manifestations, cardiac involvement, laboratory findings, therapy administered, response to treatment, and outcome. Eighty-four patients with KD were enrolled. Of these, five (6 %) met the criteria for KSS. Patients with KSS had higher values of C-reactive protein (p = 0.005), lower hemoglobin levels (p = 0.003); more frequent hyponatremia (p = 0.004), hypoalbuminemia (p = 0.004), and coagulopathy (p = 0.003); and increase in cardiac troponins (p = 0.000). Among the KSS patients, three had a coronary artery involvement, but none developed a permanent aneurysm. Intravenous immunoglobulin resistance was more frequent in the KSS group, although not significantly so (3/5, 60 % vs. 23/79, 30 %, P = NS). None of the five cases was fatal, and all recovered without sequelae. KSS patients are more likely to have higher rates of cardiac involvement. However, most cardiovascular abnormalities resolved promptly with therapy.
Literatur
3.
Zurück zum Zitat Wang W, Zhu WH, Qi YQ, Fu SL, Gong FQ (2012) Cardiogenic shock: do not forget the possibility of Kawasaki disease. Turk J Pediatr 54:86–89PubMed Wang W, Zhu WH, Qi YQ, Fu SL, Gong FQ (2012) Cardiogenic shock: do not forget the possibility of Kawasaki disease. Turk J Pediatr 54:86–89PubMed
11.
Zurück zum Zitat Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733. doi:10.1542/peds.2004-2182 CrossRefPubMed Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733. doi:10.​1542/​peds.​2004-2182 CrossRefPubMed
12.
Zurück zum Zitat Dieckmann RA (2007) Pediatric assessment. In: Gausche-Hill M, Fuchs S, Yamamoto L (eds) APLS: the pediatric emergency medicine resource, 4th edn. Jones and Bartlett, Sudbury, pp 20–51 Dieckmann RA (2007) Pediatric assessment. In: Gausche-Hill M, Fuchs S, Yamamoto L (eds) APLS: the pediatric emergency medicine resource, 4th edn. Jones and Bartlett, Sudbury, pp 20–51
14.
Zurück zum Zitat Fitzmaurice L, Gerardi JM (2007) Cardiovascular system. In: Gausche-Hill M, Fuchs S, Yamamoto L (eds) APLS: the pediatric emergency medicine resource, 4th edn. Jones and Bartlett, Sudbury, pp 106–145 Fitzmaurice L, Gerardi JM (2007) Cardiovascular system. In: Gausche-Hill M, Fuchs S, Yamamoto L (eds) APLS: the pediatric emergency medicine resource, 4th edn. Jones and Bartlett, Sudbury, pp 106–145
15.
Zurück zum Zitat McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW (2007) Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 116:174–179. doi:10.1161/CIRCULATIONAHA.107.690875 CrossRefPubMed McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW (2007) Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 116:174–179. doi:10.​1161/​CIRCULATIONAHA.​107.​690875 CrossRefPubMed
18.
Zurück zum Zitat Gatterre P, Oualha M, Dupic L, Iserin F, Bodemer C, Lesage F, Hubert P (2012) Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 38:872–878. doi:10.1007/s00134-012-2473-8 CrossRefPubMed Gatterre P, Oualha M, Dupic L, Iserin F, Bodemer C, Lesage F, Hubert P (2012) Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 38:872–878. doi:10.​1007/​s00134-012-2473-8 CrossRefPubMed
19.
Zurück zum Zitat Zulian F, Falcini F, Zancan L, Martini G, Seccheri S, Luzzatto C, Zacchello F (2003) Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 142:731–735, http://dx.doi.org/10.1067/mpd.2003.232 CrossRefPubMed Zulian F, Falcini F, Zancan L, Martini G, Seccheri S, Luzzatto C, Zacchello F (2003) Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 142:731–735, http://​dx.​doi.​org/​10.​1067/​mpd.​2003.​232 CrossRefPubMed
22.
Zurück zum Zitat Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP (2007) Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Eng J Med 356:663–675. doi:10.1056/NEJMoa061235 CrossRef Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP (2007) Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Eng J Med 356:663–675. doi:10.​1056/​NEJMoa061235 CrossRef
23.
Zurück zum Zitat Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H (2013) Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr 163:521–526. doi:10.1016/j.jpeds.2013.01.022 CrossRefPubMed Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H (2013) Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr 163:521–526. doi:10.​1016/​j.​jpeds.​2013.​01.​022 CrossRefPubMed
25.
Zurück zum Zitat Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379:1613–1620. doi:10.1016/S0140-6736(11)61930-2 CrossRefPubMed Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379:1613–1620. doi:10.​1016/​S0140-6736(11)61930-2 CrossRefPubMed
Metadaten
Titel
Describing Kawasaki shock syndrome: results from a retrospective study and literature review
verfasst von
Andrea Taddio
Eleonora Dei Rossi
Lorenzo Monasta
Serena Pastore
Alberto Tommasini
Loredana Lepore
Gabriele Bronzetti
Edoardo Marrani
Biancamaria D’Agata Mottolese
Gabriele Simonini
Rolando Cimaz
Alessandro Ventura
Publikationsdatum
26.05.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 1/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3316-8

Weitere Artikel der Ausgabe 1/2017

Clinical Rheumatology 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.